CHRISTINA MAY MORAN DE BRITO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
42 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 42
bookPart Modelo assistencial do serviço de reabilitação(2014) BRITO, Christina May Moran de; BATTISTELLA, Linamara Rizzo; BAIA, Wania Regina MolloconferenceObject How much time is necessary to assess maximal inspiratory pressure by unidirectional expiratory valve method in subjects without artificial airway?(2014) GRAMS, Samantha; KIMOTO, Karen; AZEVEDO, Elen; BRITO, Christina; YAMAGUTI, WellingtonbookPart Reabilitação de Pacientes Oncológicos(2016) BRITO, Christina May Moran de; CECATTO, Rebeca Boltes; BATTISTELLA, Linamara RizzobookPart Avaliação da qualidade de vida(2014) VELAR, Camila Molina; BRITO, Christina May Moran de; SOUZA, Luiz Paulo Marques de; ANDRADE, Lydia Caldeira Tavares de OliveirabookPart Reabilitação após cirurgia da cabeça e pescoço(2013) BRITO, Christina May Moran de; CAMARGO, Fernanda Pereira; TONINI, Paula; BATISTELLA, Linamara Rizzo- Botulinum toxin type A as an adjunct treatment to radiation-induced trismus(2013) ANDRADE, R. G.; LIMA, M. C.; BRITO, C. M. M.Purpose of study: To report a case of trismus (lockjaw) that began after completion of radiation therapy for head and neck cancer that we treated with botulinum toxin type A. Methods used: Case report. Summary of results: A white woman, 60 years old, was diagnosed with squamous cell carcinoma (SCC) of the left oral mucosa in April 2010. She underwent resection of the SCC in June 2010 with neck dissection and construction of a left supraclavicular flap. Subsequently, she underwent radiotherapy from 25 October 2010 to 14 December 2010. About 30 days after the radiation therapy, she noticed a decreased range of motion associated with jaw pain, and she experienced difficulty with feeding and oral hygiene. She was referred to speech therapy for rehabilitation but had little improvement. In our first physiatric evaluation on 13 June 2011, we identified a maximal inter-incisal distance of 0.5 cm, pain score assessed by visual analog scale (VAS) of 4, and Short Form 36 (SF-36) score of 676. We requested a facial and temporomandibular joint MRI, which eliminated recurrence of disease, osteonecrosis and muscle fibrosis as possible causes of the trismus. We chose to treat her trismus with botulinum toxin type A (Prosigne®, Lanzhou Biological Products Institute, Lanzhou, China), with 60 U in the masseter and 40 U in the temporalis muscle, with resumption of the speech therapy exercises while we monitored the toxin therapy. Two weeks after injection, the patient showed a maximal inter-incisal distance of 2.0 cm, a 2-point improvement in the VAS, an improved SF-36 score of 742, and she reported relief of pain. She even reported complete resolution of a previous headache, which she had not mentioned in her first evaluation. Conclusions: We suggest the use of botulinum toxin type A as an adjunct treatment to radiation-induced trismus, especially in severe cases that are refractory to conventional treatment. Trials with this treatment are indicated in order to evaluate the role of BTX-A in trismus.
bookPart Semiologia do paciente com incapacidade(2021) BRITO, Christina May Moran debookPart Cuidados em pacientes citopênicos(2014) KIMURA, Aline Ayako; ROTTA, Bruna Peruzzo; RODRIGUES, Carolina Carvalho Veloso; PINTO, Cesar Antonio; BRITO, Christina May Moran de; SILVA, Conceição Aparecida Vitoriano Souza; REIS, FabianabookPart Reabilitação da disfunção vesicoesfincteriana(2014) BRITO, Christina May Moran de; SCHMIDT, Fernanda Mateus Queiroz; CANETTIERI, Maíra Grizzo; QUINTANA, Mônica Millinkovic de la; ANDRADE, Paulo Antonio da Silva; GIMENEZ, Tânia Maio Matheus- Effects of transcutaneous electrical nerve stimulation on chemotherapy-induced peripheral neuropathy symptoms (CIPN): A preliminary case-control study(2017) TONEZZER, T.; CAFFARO, L. A. M.; MENON, K. R. S.; SILVA, F. C. B. da; BRITO, C. M. M. de; SARRI, A. J.; CASAROTTO, R. A.[Purpose] The aim of this double-blind, randomized and placebo-controlled study is to investigate the effects of Transcutaneous Electrical Nerve Stimulation for reducing the side effects of Chemotherapy-induced Peripheral Neuropathy in cancer patients undergoing chemotherapy with oxaloplatin or paclitaxel. [Subjects and Methods] Twenty-four patients were randomly allocated into two groups: active or placebo stimulation. All patients were assessed for pain, numbness/tingiling, frequency of symptoms, and quality of life. The transcutaneous Electrical Nerve Stimulation device was applied daily with modulating frequencies ranging between 7 Hz and 65 Hz in distal limb regions during three cycles of chemotherapy (45 days). The other stimulation parameters were: pulse duration of 200 μsec, intensity at the highest tolerable level, and increases in intensity when it diminished. [Results] The data showed no difference between active or placebo groups in terms of pain, numbness/tingling, frequency of symptoms or impact on daily life activities. [Conclusion] These results suggest that Transcutaneous Electrical Nerve Stimulation applied in the frequency variation mode was not proven to be effective to improve the symptoms of Chemotherapy-induced Peripheral Neuropathy during chemotherapy cycles. There was no worsening of symptoms in subsequent cycles of the onset of symptoms of the disease. © 2017 The Society of Physical Therapy Science.